BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18571811)

  • 1. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase.
    Seimiya M; Tomonaga T; Matsushita K; Sunaga M; Oh-Ishi M; Kodera Y; Maeda T; Takano S; Togawa A; Yoshitomi H; Otsuka M; Yamamoto M; Nakano M; Miyazaki M; Nomura F
    Hepatology; 2008 Aug; 48(2):519-30. PubMed ID: 18571811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma.
    Di Tommaso L; Destro A; Fabbris V; Spagnuolo G; Laura Fracanzani A; Fargion S; Maggioni M; Patriarca C; Maria Macchi R; Quagliuolo M; Borzio M; Iavarone M; Sangiovanni A; Colombo M; Roncalli M
    Hepatology; 2011 May; 53(5):1549-57. PubMed ID: 21520170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formiminotransferase Cyclodeaminase Suppresses Hepatocellular Carcinoma by Modulating Cell Apoptosis, DNA Damage, and Phosphatidylinositol 3-Kinases (PI3K)/Akt Signaling Pathway.
    Chen J; Chen Z; Huang Z; Yu H; Li Y; Huang W
    Med Sci Monit; 2019 Jun; 25():4474-4484. PubMed ID: 31203308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
    Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
    Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
    Swanson BJ; Yearsley MM; Marsh W; Frankel WL
    Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
    Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
    Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
    Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
    Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
    Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a yeast two-hybrid system to identify FTCD as a new regulator for HIF-1α in HepG2 cells.
    Yu Z; Ge Y; Xie L; Zhang T; Huang L; Zhao X; Liu J; Huang G
    Cell Signal; 2014 Jul; 26(7):1560-6. PubMed ID: 24686083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.
    McKnight R; Nassar A; Cohen C; Siddiqui MT
    Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.
    Fujiwara M; Kwok S; Yano H; Pai RK
    Cancer Cytopathol; 2012 Aug; 120(4):230-7. PubMed ID: 22434791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis.
    Yeo M; Na YM; Kim DK; Kim YB; Wang HJ; Lee JA; Cheong JY; Lee KJ; Paik YK; Cho SW
    Proteomics; 2010 Jan; 10(2):266-76. PubMed ID: 19904771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
    Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
    Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.
    Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP
    J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
    Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
    J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.